GENEVA--(BUSINESS WIRE)--Endosense, a medical technology company focused on enabling the broad adoption of catheter ablation for the treatment of cardiac rhythm disorders, has launched the TOCCATA (TOuCh+ for CATheter Ablation) clinical study to evaluate the safety of the TactiCath™ system with enrollment gaining momentum. TOCCATA is a 70 patient European multi-center safety study. Constructed to gain the CE mark for the treatment of atrial arrhythmias, secondary endpoints were designed to evaluate the value of force-sensing in successfully impacting outcomes of the ablation procedure.
